CA3033564A1 - Acetyl-leucine for neurodegenerative diseases - Google Patents

Acetyl-leucine for neurodegenerative diseases Download PDF

Info

Publication number
CA3033564A1
CA3033564A1 CA3033564A CA3033564A CA3033564A1 CA 3033564 A1 CA3033564 A1 CA 3033564A1 CA 3033564 A CA3033564 A CA 3033564A CA 3033564 A CA3033564 A CA 3033564A CA 3033564 A1 CA3033564 A1 CA 3033564A1
Authority
CA
Canada
Prior art keywords
acetyl
leucine
patient
disease
neurodegenerative disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3033564A
Other languages
English (en)
French (fr)
Inventor
Michael Strupp
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intrabio Ltd
Original Assignee
Intrabio Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59859424&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA3033564(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB1613829.9A external-priority patent/GB201613829D0/en
Priority claimed from GBGB1702551.1A external-priority patent/GB201702551D0/en
Priority claimed from GBGB1705766.2A external-priority patent/GB201705766D0/en
Priority claimed from GBGB1706867.7A external-priority patent/GB201706867D0/en
Application filed by Intrabio Ltd filed Critical Intrabio Ltd
Publication of CA3033564A1 publication Critical patent/CA3033564A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/46—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Addiction (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Anesthesiology (AREA)
  • Transplantation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA3033564A 2016-08-11 2017-08-11 Acetyl-leucine for neurodegenerative diseases Pending CA3033564A1 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
GB1613829.9 2016-08-11
GBGB1613829.9A GB201613829D0 (en) 2016-08-11 2016-08-11 Therapeutic agents for neurodegenerative diseases, lysosomal storage disorders and neurodegenerative diseases associated with defects in lysosomal storage
GBGB1702551.1A GB201702551D0 (en) 2017-02-16 2017-02-16 Therapeutic agents for neurodegenerative diseases, lysosomal storage disorders and neurodegenerative diseases associated with defects in lysosomal storage
GB1702551.1 2017-02-16
GBGB1705766.2A GB201705766D0 (en) 2017-04-10 2017-04-10 Therapeutic agents for neurodegenerative diseases, lysosomal storage disorders and neurodegenerative diseases associated with defects in lysosomal storage
GB1705766.2 2017-04-10
GB1706867.7 2017-04-28
GBGB1706867.7A GB201706867D0 (en) 2017-04-28 2017-04-28 Therapeutic agents for neurodegenerative diseases, lysosomal storage disorders and neurodegenerative diseases associated with defects in lysosomal storage
PCT/IB2017/054929 WO2018029658A1 (en) 2016-08-11 2017-08-11 Therapeutic agents for neurodegenerative diseases

Publications (1)

Publication Number Publication Date
CA3033564A1 true CA3033564A1 (en) 2018-02-15

Family

ID=59859424

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3033564A Pending CA3033564A1 (en) 2016-08-11 2017-08-11 Acetyl-leucine for neurodegenerative diseases

Country Status (28)

Country Link
US (3) US12144792B2 (enExample)
EP (3) EP3583940A1 (enExample)
JP (3) JP6957602B2 (enExample)
KR (4) KR20220093385A (enExample)
CN (4) CN116492328A (enExample)
AU (3) AU2017308865B2 (enExample)
BR (1) BR112019002730A2 (enExample)
CA (1) CA3033564A1 (enExample)
CY (1) CY1121930T1 (enExample)
DK (1) DK3416631T3 (enExample)
ES (1) ES2733677T3 (enExample)
HR (1) HRP20191055T1 (enExample)
HU (1) HUE045043T2 (enExample)
IL (3) IL310799A (enExample)
LT (1) LT3416631T (enExample)
MA (2) MA47521A (enExample)
MD (1) MD3416631T2 (enExample)
ME (1) ME03454B (enExample)
MX (3) MX383499B (enExample)
PL (1) PL3416631T3 (enExample)
PT (1) PT3416631T (enExample)
RS (1) RS59048B1 (enExample)
RU (1) RU2756519C2 (enExample)
SG (1) SG11201901063SA (enExample)
SI (1) SI3416631T1 (enExample)
SM (1) SMT201900370T1 (enExample)
TN (1) TN2019000033A1 (enExample)
WO (1) WO2018029658A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10219815B2 (en) 2005-09-22 2019-03-05 The Regents Of The University Of Michigan Histotripsy for thrombolysis
JP6979882B2 (ja) 2015-06-24 2021-12-15 ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン 脳組織の治療のための組織破砕療法システムおよび方法
HUE052837T2 (hu) 2016-08-11 2021-05-28 Intrabio Ltd Lizoszóma-tárolási betegségre irányuló gyógyászati készítmények és alkalmazásaik
BR112019002730A2 (pt) 2016-08-11 2019-05-14 Intrabio Ltd acetil-leucina, ou um sal farmaceuticamente aceitável da mesma, para uso em um método de tratamento de uma doença neurodegenetativa
GB201709459D0 (en) 2017-06-14 2017-07-26 Intrabio Ltd Treatment for migraine
SMT202500483T1 (it) * 2017-10-18 2026-01-12 Intrabio Ltd Agenti terapeutici da utilizzare nel trattamento della sindrome delle gambe senza riposo
SI3752141T1 (sl) * 2018-02-15 2024-09-30 Intrabio Ltd. Acetil-levcin za uporabo pri zdravljenju sindroma nemirnih nog
CN113286552B (zh) 2018-11-28 2025-05-02 希斯托索尼克斯公司 组织摧毁术系统及方法
KR20250022899A (ko) * 2018-12-06 2025-02-17 인트라바이오 리미티드 아세틸-류신의 중수소화된 유사체
SG11202109512SA (en) * 2019-03-02 2021-09-29 Intrabio Ltd Leucine, acetyl leucine, and related analogs for treating disease
WO2021055443A1 (en) * 2019-09-17 2021-03-25 Hoffmann-La Roche Inc. Improvements in personalized healthcare for patients with movement disorders
WO2021144720A1 (en) * 2020-01-13 2021-07-22 Intrabio Ltd Treatment of late-onset neurodegenerative diseases in heterozygous npc1 gene mutation carriers
CA3179105A1 (en) * 2020-05-22 2021-11-25 Michael Strupp The combination of acetyl leucine and 4-aminopyridine or acetazolamide for treating ataxia
WO2022264037A1 (en) * 2021-06-14 2022-12-22 Intrabio Ltd. Branched-chain amino acid derivatives to treat disease
US20240149078A1 (en) 2022-10-28 2024-05-09 Histosonics, Inc. Histotripsy systems and methods
KR20260003742A (ko) 2023-04-20 2026-01-07 히스토소닉스, 인크. 치료 계획 및 요법을 위한 사용자 인터페이스들 및 작업 흐름들을 포함하는 히스토트립시 시스템들 및 연관된 방법들
WO2025151578A1 (en) * 2024-01-12 2025-07-17 Intrabio Inc. N-acetyl-leucine for use in the treatment of prodromal alpha-synucleinopathies
WO2025163129A1 (en) * 2024-02-01 2025-08-07 Intrabio Ltd. Acetyl-leucine for treating parkinson´s disease
US12403111B2 (en) 2024-02-02 2025-09-02 SynGAP Research Fund Compositions and methods for treating neurodevelopmental disorders
WO2025175092A1 (en) * 2024-02-14 2025-08-21 Intrabio Inc. Acetyl leucine for treating syngap1-related disorders

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060063827A1 (en) * 2004-09-23 2006-03-23 Yu Ruey J Systemic administration of therapeutic amino acids and N-acetylamino acids
US20050222209A1 (en) * 2004-04-01 2005-10-06 Zeldis Jerome B Methods and compositions for the treatment, prevention or management of dysfunctional sleep and dysfunctional sleep associated with disease
FR2905600B1 (fr) 2006-09-13 2010-01-15 Pf Medicament Traitement des vertiges par l'acetyl-l-leucine.
WO2008101693A2 (en) 2007-02-22 2008-08-28 Beiersdorf Ag Cosmetic and pharmaceutical applications of n-acylated amino acids and structurally related compounds
TN2010000251A1 (fr) * 2010-06-03 2011-11-11 Rekik Raouf N-acetyl-dl-leucine medicament neuro et retino protecteur
TN2010000566A1 (en) * 2010-12-03 2012-05-24 Rekik Raouf Folic acid - ramipril combination : cell protective neuroprotective and retinoprotective ophtalmologic drugs
EP3062810A4 (en) * 2013-10-28 2017-05-03 Naurex Inc. Nmda receptor modulators and prodrugs, salts, and uses thereof
HUE069219T2 (hu) 2016-04-19 2025-02-28 Intrabio Ltd Acetil-leucin vagy gyógyszerészetileg elfogadható sója javított mozgásképességért
BR112019002730A2 (pt) 2016-08-11 2019-05-14 Intrabio Ltd acetil-leucina, ou um sal farmaceuticamente aceitável da mesma, para uso em um método de tratamento de uma doença neurodegenetativa

Also Published As

Publication number Publication date
RU2019106506A (ru) 2020-09-17
WO2018029658A1 (en) 2018-02-15
IL310801A (en) 2024-04-01
TN2019000033A1 (fr) 2020-07-15
MA43828B1 (fr) 2019-09-30
DK3416631T3 (da) 2019-07-15
RU2021128045A (ru) 2021-11-16
ME03454B (me) 2020-01-20
SMT201900370T1 (it) 2019-09-09
JP2022003085A (ja) 2022-01-11
AU2017308865B2 (en) 2023-04-13
EP4467195A2 (en) 2024-11-27
AU2023202121B2 (en) 2025-01-23
US20240189267A1 (en) 2024-06-13
EP3416631A1 (en) 2018-12-26
PL3416631T3 (pl) 2019-11-29
AU2017308865A1 (en) 2019-02-21
US20200179320A1 (en) 2020-06-11
AU2023202121A1 (en) 2023-05-04
JP2019524822A (ja) 2019-09-05
JP7833272B2 (ja) 2026-03-19
JP2023175762A (ja) 2023-12-12
EP4467195A3 (en) 2025-03-19
MA47521A (fr) 2021-04-21
US12144792B2 (en) 2024-11-19
US20230210799A1 (en) 2023-07-06
MA43828A (fr) 2018-12-26
IL310799A (en) 2024-04-01
CN116492328A (zh) 2023-07-28
RS59048B1 (sr) 2019-08-30
MX2024004439A (es) 2025-11-03
SI3416631T1 (sl) 2019-09-30
RU2756519C2 (ru) 2021-10-01
PT3416631T (pt) 2019-07-11
EP3583940A1 (en) 2019-12-25
MX383499B (es) 2025-03-14
MD3416631T2 (ro) 2019-09-30
JP6957602B2 (ja) 2021-11-02
HRP20191055T1 (hr) 2019-09-06
IL264641A (en) 2019-04-30
CN109789114A (zh) 2019-05-21
KR20220093385A (ko) 2022-07-05
CN121081445A (zh) 2025-12-09
KR20240068761A (ko) 2024-05-17
AU2025202077A1 (en) 2025-04-10
CY1121930T1 (el) 2020-10-14
IL264641B1 (en) 2024-03-01
MX2019001575A (es) 2019-08-01
KR20190039227A (ko) 2019-04-10
MX2021006901A (es) 2021-07-07
HUE045043T2 (hu) 2019-12-30
BR112019002730A2 (pt) 2019-05-14
IL264641B2 (en) 2024-07-01
KR102413756B1 (ko) 2022-06-27
SG11201901063SA (en) 2019-03-28
CN116459244A (zh) 2023-07-21
RU2019106506A3 (enExample) 2020-10-29
ES2733677T3 (es) 2019-12-02
EP3416631B1 (en) 2019-05-15
KR20250042197A (ko) 2025-03-26
KR102785448B1 (ko) 2025-03-21
LT3416631T (lt) 2019-08-26

Similar Documents

Publication Publication Date Title
AU2023202121B2 (en) Therapeutic agents for neurodegenerative diseases
US20260069562A1 (en) Therapeutic agents for improved mobility and cognitive function and for treating neurodegenerative diseases and lysosomal storage disorders
AU2018351709B2 (en) Therapeutic agents for neurodegenerative diseases
HK40018125A (en) Therapeutic agents for neurodegenerative diseases
RU2849887C2 (ru) Терапевтические средства против нейродегенеративных заболеваний
HK40111843A (en) Therapeutic agents for neurodegenerative diseases
HK40112206A (en) Therapeutic agents for neurodegenerative diseases
WO2025163129A1 (en) Acetyl-leucine for treating parkinson´s disease
HK1259779B (en) Therapeutic agents for neurodegenerative diseases
HK1259779A1 (en) Therapeutic agents for neurodegenerative diseases
NZ790893A (en) Therapeutic Agents for Neurodegenerative Diseases
HK40025173B (en) Therapeutic agents for use in the treatment of restless leg syndrome
HK40025173A (en) Therapeutic agents for use in the treatment of restless leg syndrome

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220721

EEER Examination request

Effective date: 20220721

EEER Examination request

Effective date: 20220721

EEER Examination request

Effective date: 20220721

EEER Examination request

Effective date: 20220721

EEER Examination request

Effective date: 20220721

EEER Examination request

Effective date: 20220721

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD

Year of fee payment: 7

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240722

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240722

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D11-D131 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR CONTINUED EXAMINATION (RCE) RECEIVED

Effective date: 20240925

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20240925

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250408

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 8TH ANNIV.) - STANDARD

Year of fee payment: 8

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250702

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250702

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D174 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR CONTINUED EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250723

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D148 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR CONTINUED EXAMINATION (NOA/CNOA) DETERMINED COMPLIANT

Effective date: 20250723

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250723

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250723

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250723

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250723